Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Sangamo Therapeutics has gained a consensus rating of "Moderate Buy" from analysts, with two hold and four buy recommendations.
• The company reported a quarterly loss of ($0.08) earnings per share, falling short of the consensus estimate of ($0.07), with revenue significantly below expectations at $18.31 million.
• Sangamo's stock price opened at $0.55 and has experienced a 52-week range from $0.41 to $3.18.

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $4.50.

A number of analysts recently weighed in on SGMO shares. Barclays reduced their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, September 4th. Finally, Wall Street Zen raised Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th.

Institutional Trading of Sangamo Therapeutics

A number of hedge funds have recently bought and sold shares of SGMO. Wasatch Advisors LP increased its position in shares of Sangamo Therapeutics by 17.7% in the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company's stock worth $4,376,000 after acquiring an additional 1,215,653 shares in the last quarter. Engineers Gate Manager LP boosted its stake in Sangamo Therapeutics by 101.7% in the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 44,078 shares during the period. Invesco Ltd. boosted its stake in Sangamo Therapeutics by 40.6% in the 2nd quarter. Invesco Ltd. now owns 680,452 shares of the biopharmaceutical company's stock worth $368,000 after purchasing an additional 196,558 shares during the period. XTX Topco Ltd purchased a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $41,000. Finally, Geode Capital Management LLC raised its stake in Sangamo Therapeutics by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company's stock valued at $1,263,000 after purchasing an additional 48,829 shares during the period. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Price Performance

NASDAQ:SGMO remained flat at $0.53 during mid-day trading on Friday. The company had a trading volume of 3,709,355 shares, compared to its average volume of 4,383,023. The business's fifty day moving average price is $0.53 and its two-hundred day moving average price is $0.63. Sangamo Therapeutics has a 1 year low of $0.41 and a 1 year high of $3.18. The company has a market cap of $160.45 million, a price-to-earnings ratio of -1.83 and a beta of 1.20.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $18.31 million for the quarter, compared to the consensus estimate of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. As a group, research analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.